News

HS3ST2 enzyme expression increased in Alzheimer’s brains


 

References

The enzyme heparan sulphate 3-O-sulphotransferase 2 (HS3ST2) was expressed significantly more frequently in the hippocampi of Alzheimer’s patients than in the brains of controls, according to a study.

The study showed that 3-O-sulphated heparan sulphates, which are produced by the HS3ST2 enzyme, cause tau proteins to be abnormally phosphorylated.

The study results “position intracellular 3-O-sulphated heparan sulphates, and the enzymes responsible for their high sulphation in neurons, as central modulators of tau abnormal phosphorylation before it occurs,” wrote PhD student Julia Elisa Sepulveda-Diaz of Centre National de la Recherche Scientifique, Paris, and her colleagues. “This opens a wide area of research in the field of glyco-neurobiology, positioning HS3ST2 and its products as potential key players in the development and evolution of tau pathology, with the therapeutic consequences that this implies,” the researchers noted. Read the full study in Brain (10.1093/brain/awv056).

Recommended Reading

Consortium opens Alzheimer’s data to global research community
MDedge Psychiatry
GAO calls for expanded efforts to reduce antipsychotic use in older dementia patients
MDedge Psychiatry
Study identifies factors for minimizing the impact of Alzheimer’s genetic risk
MDedge Psychiatry
Autopsy studies verify flutemetamol’s ability to identify brain beta-amyloid
MDedge Psychiatry
Dose-related increase in mortality with antipsychotics in dementia
MDedge Psychiatry
Potential link between pulse pressure and dementia onset found
MDedge Psychiatry
Alzheimer’s disease biomarkers have limited association with each other
MDedge Psychiatry
Investigational cancer drug now tested for treating Alzheimer’s
MDedge Psychiatry
Olfactory deficits may signal cognitive decline
MDedge Psychiatry
Gene newly linked to mild Alzheimer’s pathology
MDedge Psychiatry